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ABSTRACT Congenital diaphragmatic hernia (CDH) is a rare congenital anomaly characterised by a
diaphragmatic defect, persistent pulmonary hypertension (PH) and lung hypoplasia. The relative
contribution of these three elements can vary considerably in individual patients. Most affected children
suffer primarily from the associated PH, for which the therapeutic modalities are limited and frequently
not evidence based. The vascular defects associated with PH, which is characterised by increased
muscularisation of arterioles and capillaries, start to develop early in gestation. Pulmonary vascular
development is integrated with the development of the airway epithelium. Although our knowledge is still
incomplete, the processes involved in the growth and expansion of the vasculature are beginning to be
unravelled. It is clear that early disturbances of this process lead to major pulmonary growth
abnormalities, resulting in serious clinical challenges and in many cases death in the newborn. Here we
provide an overview of the current molecular pathways involved in pulmonary vascular development.
Moreover, we describe the abnormalities associated with CDH and the potential therapeutic approaches
for this severe abnormality.
Normal pulmonary vascular development
Human lung development can be divided into different stages based on histology, starting with the
embryonic stage at 4 weeks of gestation, followed by the pseudoglandular stage in which branching of the
lung buds continues. During the canalicular stage, starting at ∼16 weeks of gestation, the terminal
bronchioli are formed. From 24 weeks of gestation until term, the saccular stage, airspaces widen and
alveoli are formed. During the alveolar stage, which persists into the postnatal period up to 3 years of age,
maturation of the airways occurs [1]. Concomitant with the expansion of the airways is the adaptation of
the microvasculature to optimise the exchange of oxygen and carbon dioxide between the blood and the
airways. We and others have shown that very early in lung development pulmonary vessels are present and
connected to the systemic circulation. The vasculature develops in close relation with the airways and is a
rate-limiting factor in branching morphogenesis [2–4]. This implies that the pulmonary vasculature plays
an important role in lung development. The formation of new blood vessels primarily occurs through
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sprouting of new capillaries from pre-existing vessels at the growing tips of the branching epithelium, a
process referred to as distal angiogenesis [4]. The newly formed endothelial tubes need to be stabilised by
perivascular cells, pericytes, to become functional capillaries in a platelet derived growth factor-β
dependent manner [5, 6]. Little is known about the pericyte population during lung development, but
pericytes have been shown to originate from Wnt2+/Gli1+/Isl1+ multipotent cardiopulmonary mesoderm
progenitors [7].
Pulmonary vascular resistance is high during gestation and decreases rapidly after birth under the
influence of breathing movements, gas exchange and the release of vasoactive factors of the endothelin
(ET), nitric oxide (NO) and prostacyclin (PGI2) pathways [8, 9] (figure 1). The ET pathway is activated by
three ligands: ET-1, ET-2 and ET-3, of which ET-1 is the most common isoform [10, 11]. The ET-1
precursor protein, prepro-ET-1, is cleaved by furin into big-ET-1, which is subsequently processed to its
active form by the endothelin-converting enzyme-1 and binds and activates two different G-protein
coupled receptors, ETA and ETB, with equal affinity. The ETA receptor is located at the cell surface of
vascular smooth muscle cells and induces vasoconstriction and cell proliferation by activating
phospholipase C, whereas the ETB receptor is located mainly in the cell membrane of the endothelium
and induces vasodilation by regulating the release of NO and PGI2 [11, 12]. Furthermore, ET-1 promotes
cell growth, cell adhesion and thrombosis and is increased in lung tissue of patients with pulmonary
hypertension (PH). A negative feedback loop is triggered by NO that reduces the affinity of the ETA
receptor for ET-1 and can therefore prevent ET-1-mediated signalling [12]. NO can be synthesised by one
of three different NO synthases (NOS), of which endothelial (e)NOS is the most important synthase
involved in the regulation of the pulmonary vascular tone and is highly expressed in the endothelial cells
[13]. NO can bind to its receptor, soluble guanylyl cyclase, which can synthesise the second messenger
cyclic guanosine monophosphate, thereby inducing vasodilation. The third important pathway involves
prostaglandins and thromboxanes that act on prostanoid receptors which can be divided in receptors that
cause relaxation (IP (PTGIR), EP2, EP4 and DP) or contraction (TP, EP1 and FP) of the pulmonary
vessels to change the vascular tone [14]. PGI2 is an important mediator of vasodilation which binds and
activates the prostaglandin-I2 receptor (PTGIR) [15, 16]. This activation results in vasodilation through the
release of cAMP. Apart from these vasoactive factors, retinoic acid signalling has been shown to be
important in lung development [17]. Retinoic acid is formed from vitamin A through several sequential
enzymatic reactions. Subsequently, it binds to one of the retinoic acid receptors (RAR/RXR) which
subsequently modulate transcription of target genes through retinoic acid responsive element [18].
Pharmacological or genetic inactivation of retinoic acid signalling in the early foregut resulted in an
increased expression of the Wingless-type MMTV integration site family (Wnt) antagonist Dickkopf
(Dkk1) and transforming growth factor (TGF)-β, which plays an important role in airway branching and
muscularisation of the pulmonary vasculature [19]. Thus, retinoic acid integrates two important regulatory
signalling pathways, Wnt and TGF-β, in the control of Fgf10 expression.
Alveolar formation starts late in development and continues into the first years of life to expand the gas
exchanging capacity of the lung. TGF-β partly regulates the concomitant adaptation of the
microvasculature. There are two main branches in the TGF-β superfamily: the TGF-β/activin family and
the bone morphogenetic protein (BMP) family. All proteins of the TGF-β superfamily act through two
classes of serine/threonine kinase receptors: type 1 and type 2. Active TGF-β or BMP can be bound to a
specific type 2 receptor, which phosphorylates and activates a type 1 receptor. The activated type 1
receptor subsequently phosphorylates a set of receptor-regulated small body size/mothers against
decapentaplegic proteins (Smads), which form a complex with co-Smad (Smad4). TGF-β is responsible for
the phosphorylation of Smad2 and Smad 3, whereas BMP phosphorylates Smad 1, 5 and 8. Eventually, the
R-Smad/co-Smad complex modulates the transcription of target genes in the nucleus [20] (figure 2).
TGF-β signalling is necessary in vascular and airway smooth muscle cells, and in alveolar and airway
epithelial cells during late lung development [21]. Previous studies in rodents showed an arrest in
alveolarisation both in animals with upregulated TGF-β signalling [22] and after a complete blockade of
TGF-β signalling [23], indicating the important differences in TGF-β signalling between early and late
lung development.
Pulmonary vascular development in congenital diaphragmatic hernia
Congenital diaphragmatic hernia (CDH) is a rare congenital anomaly characterised by a diaphragmatic
defect, PH and lung hypoplasia. It has a worldwide incidence of ∼1 in 3000 live births [24, 25] and
mortality varies from 20% to 40% [26]. The high mortality and morbidity rates may depend on the
presence of associated malformations and/or genetic abnormalities, but are mostly due to the concomitant
PH. PH is the result of the altered development of the pulmonary vasculature, the unpredictable vascular
reactivity and the disordered process of pulmonary vascular remodelling [27, 28]. PH associated with
CDH is characterised by extensive muscularisation of the vessels, which is noticeable early in gestation
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FIGURE 1 Overview of the major pathways involved in vasodilation and vasoconstriction. ET: endothelin; ECE: endothelin-converting enzyme; ETA:
endothelin A; ETB: endothelin B; eNOS: endothelial nitric oxide synthase; sGC: soluble guanylate cyclase; COX: cyclooxygenase; PGIS:
prostaglandin synthase; PGI2: prostaglandin I2; AC: adenylate cyclase; TBXAS1: thromboxane synthase; TXA2: thromboxane.
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FIGURE 2 Overview of transforming growth factor (TGF)-β/bone morphogenetic protein (BMP) pathway. ZEB2:
zinc finger E-box binding homeobox 2; P: phosphorylation; Smad: small body size/mothers against
decapentaplegic proteins
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[29]. This indicates that the structural abnormalities start to develop when the lung is very immature. The
pathology of PH is characterised by hypermuscularisation of the midsized and large vessels and
neomuscularisation of the small capillaries [18, 28, 30, 31]. Pericytes are prime candidates to underlie and
eventually modulate the structural changes observed in PH associated with CDH [6, 32]. Differences in
pericyte coverage have been linked to other diseases with a prominent vascular component, such as
diabetic retinopathy, cancer and adult pulmonary arterial hypertension [33–35]. Additionally, co-cultured
pulmonary arterial endothelial cells and smooth muscle cells showed an altered interaction when cells were
used from a CDH sheep model [36].
Aberrations in the expression of different factors in the important vasoactive pathways have previously
been described by us and others. Increased levels of both the ETA and ETB receptors were shown in
human CDH [37] and high plasma levels of circulating ET-1 were associated with the severity of PH in
this population [38]. Studies on the expression of eNOS showed variable results, where a decrease was
found in some human studies [39], but no differences or even an increased expression of eNOS was
shown by us and others [40]. No studies have been performed on the expression of factors of the PGI2
pathway.
Finally, recent studies implicated microRNAs in the development of CDH, but it remains to be seen
whether the changes observed in miR-200b and miR-10a are a cause or a consequence of CDH [41, 42].
Treatment of pulmonary vascular defects in CDH
The significance of PH in the mortality and morbidity of patients with CDH has been increasingly
recognised. Extracorporeal membrane oxygenation may be provided as a treatment of last resort to relieve
the respiratory distress of these children and provide time for the pulmonary vasculature to adjust to the
postnatal increased flow to the pulmonary vascular bed. However, the persistent PH requires more
targeted approaches to improve the oxygenation of these children. The first vasodilators used in these
critically ill newborns with PH, tolazoline [43], an α-adrenergic receptor antagonist, and prostacyclin [44],
a PGI2 agonist, resulted in variable results. Tolazoline infusion showed a response in 21 out of 36 neonatal
patients with lung disease, where systemic hypotension and bleeding tendency were seen as a severe
side-effect in several patients [43]. Treatment with PGI2 improved pulmonary arterial pressure and
oxygenation in two out of three neonatal patients with idiopathic PH and PH caused by meconium
aspiration. However, it had no beneficial effect in two patients with CDH, whereas systemic hypotension
was seen as a side-effect in one of these patients [44]. Currently, patients with CDH still respond
unpredictably to the available vasodilator therapy due to the lack of understanding of the underlying
mechanisms in the individual patient. Inhaled (i)NO is most commonly used, but studies have failed to
show its efficacy in this specific group of patients [45]. Apart from iNO, sildenafil and some prostaglandin
analogues are used as rescue therapy in a compassionate way in the most severe cases, but with variable
results [46–48]. No appropriate trials have been performed on these drugs and, with a few exceptions, no
data on pharmacokinetics are available for CDH neonates. In the near future a comparative effectiveness
trial will be conducted to compare iNO with i.v. sildenafil under the guidance of the CDH-EURO
Consortium.
Currently, the only prenatal intervention used in CDH undergoing clinical trial is fetoscopic endoluminal
tracheal occlusion (FETO), where a small balloon is inserted into the fetal trachea to temporarily block the
airway for a period of 4–6 weeks (Tracheal Occlusion to Accelerate Lung Growth (TOTAL); clinicaltrials.gov
NCT02875860) [49]. As a result, fluid is trapped in the lungs, creating internal pressure which forces the
lung to grow. This idea of blocking the airway emerged from an experiment of nature in patients with
congenital high airway obstruction syndrome resulting in big polyalveolar lungs [50]. Previous research has
shown that tracheal occlusion can indeed cause an increase in lung growth [51, 52] and removing the
balloon before birth has shown to be necessary for a better maturation of the lung by decreasing the
apoptosis of the alveolar type 2 cells, which produce surfactant, an essential compound for lung function
[53]. So far, FETO has been shown to improve survival rate in high-risk CDH patients, but at the cost of
increased morbidity and premature delivery [54–56]. The results of the TOTAL trial will hopefully provide
a more definitive answer.
Currently, treatment with vasodilators in patients with CDH is only used postnatally, where previous
research has shown already major differences in the pulmonary vasculature early in development [29]. We
and others have performed some studies on the antenatal use of the phosphodiesterase-5 inhibitor
sildenafil in different animal models of CDH, showing improvement in alveolarisation and pulmonary
vascular development [57–61]. However, the pulmonary pathology in these treated animals did not show
complete reversal to the normal lung histology.
https://doi.org/10.1183/16000617.0104-2017 4
CONGENITAL DIAPHRAGMATIC HERNIA | D.S. MOUS ET AL.
The absence of an integrated analysis of the hypermuscularisation, pericyte coverage and the pathways
regulating vascular tone, as well as the ineffective postnatal treatment in individual patients with CDH
makes it essential to obtain greater insight into the aberrant development of the pulmonary vasculature to
optimise treatment in these patients. Furthermore, adequate prenatal treatment could be beneficial for
pulmonary development and its vascular pathology, in particular in newborns with CDH.
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